The Monoclonal Antibody Strategy

Get ready for monoclonal antibody targeted vaccines!

The above sentence was written in June 2023. A year earlier, in 2022, following deployment of the mRNA vaccines, ‘viral specialists’ were already making predictions for the second generation “monoclonal antibody vaccines” (mAbs).

Maybe we’ll see a flu, COVID, RSV vaccine all combined in one.—Yuri Bochkov, 2022, Respiratory virus specialist.  [RSV = respiratory syncytial virus.]

In June 2025, RFK Jr., Health and Human Services Secretary, voted with his newly appointed vaccine committee, to recommend the RSV monoclonal antibodies (mAbs) shot for infants. According to their advice: 

RSV infects nearly everyone by the time they’re 2. It causes cold symptoms, affecting the breathing passages and lungs, according to the CDC. In the United States, about 58,000 children younger than 5 are hospitalized for RSV each year, and several hundred die. —June 26, 2025

They also unanimously voted to recommend the flu vaccines for all Americans six months and older.

Among the eight new members of the Department of HHS vaccine committee is a Dr. Robert Malone, co-developer of a different mAbs shot; RelcoVax. You may remember the name as someone who once worked deeply with the pharmaceutical industry to co-develop mRNA nanotechnology… that was also a strategy… strategically deployed without FDA approval in 2021. He later denounced mRNA technology. However, as Malone has dedicated his life to vaccines, he is not “anti-vaccine” as the media likes to portray him. Rather, he is pro-second generation mAbs vaccines! [See portion of resume and full bio]. 

Dr. Malone is a specialist in clinical research, medical affairs, regulatory affairs, project management, proposal management (large grants and contracts), vaccines and biodefense.

The stated mission of RFK Jr. and Dr. Malone is to ensure vaccine safety, transparency, and bioethics.  Of course, there are now mAbs vaccines for colds and flus in development. 

However, vaccine education websites clarify that monoclonal antibody therapy is NOT a vaccine.  And, there are reasons why there has never been a universal cold and flu vaccine before.  According to Yury Bochkov, respiratory virus specialist at the University of Wisconsin School of Medicine and Public Health:

Considering there are more than 100 types of A and B rhinoviruses, you would have to put all 100 types in one vial of vaccine in order to enable protection” against just A and B rhinoviruses. 

Bochkov was suggesting the mAbs-strategy provides an endless loop of “injectables” for vaccine makers. 

But mAbs are not vaccines. 

RelCoVax™

In 2021, Dr. Malone advocated for the 2-antigen protein vaccine, a second-generation multivalent SARS-CoV-2 vaccine. aka, a mAb vaccine called RelCoVax.  As a key architect of the mRNA vaccine technology, Malone advocated for a four-pronged approach: See Malone’s Covid Conversation interview here.

1) Use the vaccine for those at highest risk, such as the elderly;
2) Provide early treatment to help keep people out of the hospital;
3) Provide tools for individuals to assess their own risk
4) Provide tools for individuals to test whether they have Covid.

Note: This is the  same ‘four pronged ‘strategy’ outlined by World Health Organization Director General, Dr Tedros Adhanom Ghebreyesus on March 13, 2020

Vaccine History Refresher 

Vaccines were first developed under a strategy to stimulate and imitate natural antibody production in the body. This artificial manipulation of the immune system by scientists became known as Acquired Immunity (vs Natural Immunity). However, vaccine-induced, immunity is not long-term or reliable. A tell-tale artifact of vaccines is that their protection wanes overtime.

So, scientists set out to create a “new and improved” vaccine. 

Enter the mRNA experimental COVID vaccines! These nanotechnology injectables are a mix of proteins from different viruses from the Family Coronaviridae, as well as a slew of metamaterials (graphene nanoparaticles). They are not designed to stimulate antibody production, because they are not true vaccines. Scientists call this gene-therapy. They are also being used as Cancer therapy.

The role of nanotechnology instructs the genome to create new proteins (antigens) not previously known to the body. 

Unfortunately, the negative consequences of mRNA nanotechnology are many.  mRNA jabs come with collateral damage that can dismantle the immune system. Some adverse events result in autoimmune diseases such as hemolytic anemia or Graves disease. Symptoms include premature aging:

This reduction in epigenetic clock estimates was significantly related to chronological age and immune cell-type compositional changes in B cells and plasmablasts pre- and post-vaccination. –Pang et al., Journal of Front Genet, June 2022

Hence the need for mAbs:

Monoclonal antibodies may be required for people who cannot develop or maintain an adequate immune response after vaccination.  — Covid19 Prevention Network

Monoclonal Antibodies: NOT Vaccines

They are a type of targeted cancer therapy, which means they are designed to interact with specific targets. —National Cancer Institute

Monoclonal antibodies (mAbs) are a targeted platform, injected into the body. But, they are not vaccines.

Think of it as a military-type, seek-and-destroy mission that picks up where the mRNA vaccine leaves off. The mAbs technology claims to specifically target a certain antigen for removal.  In essence, mAbs counteract the effects of the mRNA vaccines. 

Specifically, where the mRNA vaccine encodes the DNA to create a foreign “spike protein” in the body, then a SARS-Cov monoclonal antibody vaccine targets that spike protein for removal.  Create the problem then destroy the problem. 

There are dozens of new monoclonal antibodies soon to be released. A handy tracker of monoclonal antibodies in development for COVID-19 is maintained by The Antibody Society.

What are the risks?

The Risks of Injecting Antibodies (mAbs)

Monoclonal antibody therapies are described as “antigen based.” They are developed to be used in patients at risk for developing severe disease to decrease hospitalizations and mortality.

According to the government-funded, 2023 NIH study, “Benefits and Risks of Administering Monoclonal Antibody Therapy for Coronavirus (COVID-19)”  there are serious risks for this group, including:

1. Some monoclonal antibodies are EUA (Emergency Use Authorized], not FDA-approved.
2. As viruses evolve and mutate, mAbs become ineffective (fail to neutralize activity). This is the reason cold and flu vaccines do not work.
3. Adverse events such as transfusion reactions and anaphylaxis are documented.
4. As of January 2023, all previously authorized monoclonal antibodies have lost their EUAs for the treatment of COVID-19 due to the resistance demonstrated by this variant.
5. mAbs may promote selection for escape mutants.
6. Complications include infusion-related reactions are characterized by flushing, fever/chills, back or abdominal pain, nausea/vomiting, pruritus, or skin rashes.
7. Not authorized for use in severe illnesses requiring high-flow oxygen or mechanical ventilation due to this potential for harm.
8. Not indicated for patients with advanced age and/or underlying medical conditions that increase the risk of severe disease.
9. Not indicated for treating acute COVID-19.
10. Mortality is significantly increased in older, sick, people compared to younger healthy individuals.

Despite the problems, in 2021, FDA had already approved the 100th mAB product.

The “antigen based” technology is the approach of the Gates Foundation for the next pandemic event.

Novovax™

One of many WHO-approved vaccines is Novavax, a 2022 Covid booster vaccine authorized for adolescents 12-17. Side effects include: difficulty breathing, face or throat swelling, fast heartbeat, rash, dizziness and weakness.

A 2024 article in the journal Nature concluded: “The immune responses to Novavax’s licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood.” 

Speaking as a doctor, [one “expert”] said that he has looked at studies of a vaccine called Novavax that does not use mRNA technology but is antigen-based, and he’s very encouraged by it…. 2021 LifeSiteNews. He also said, ‘Natural immunity is the best of all forms of immunity,’ —Dr. Peter McCullough, 2021 LifeSiteNews

Questions: 

Why create an artificial, injectable, monoclonal antibody treatment when the body naturally creates original antibodies?

Why create nano-antibodies that target antigens (proteins) created by mRNA injections?

Is the strategy to create longterm customers who lack an immune system?